FDA Approves Lumateperone sNDA for Schizophrenia Relapse Prevention

The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for lumateperone (Caplyta; Johnson & Johnson) based on phase 3 data demonstrating a significant reduction in relapse risk among adults with schizophrenia.

The label update, announced April 27, 2026, adds long-term relapse prevention data to the existing prescribing information for the atypical antipsychotic, which is already approved for schizophrenia, major depressive disorder (MDD) as adjunctive therapy, and bipolar depression.¹

"Relapse can be one of the most disruptive aspects of schizophrenia, often undoing hard-won progress and increasing the risk of hospitalization," Christoph U. Correll, MD, Clinical Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell, New York, said in press release. "These Phase 3 results—showing significantly longer time to relapse with 84% remaining relapse free over 6-months—provide clinicians with another tool that can offer long-term stability for people living with schizophrenia."¹

Study Design and Efficacy Findings

The sNDA was supported by Study 304, a multicenter, multinational, double-blind, placebo-controlled, randomized withdrawal trial. In this study, adult patients with schizophrenia first entered an 18-week open-label stabilization phase during which they received lumateperone 42 mg daily. Those who met predefined stabilization criteria were then randomized to continue lumateperone 42 mg (n = 110) or switch to placebo (n = 114) for up to 26 weeks.¹

The primary endpoint was time to first symptomatic relapse during the double-blind phase. Lumateperone significantly extended time to relapse compared with placebo (P = .0002), with a 63% lower relative risk of relapse (hazard ratio, 0.37). Eighty-four percent of patients in the lumateperone group remained relapse-free over the 6-month double-blind period. The drug also significantly delayed time to all-cause treatment discontinuation, including relapse, which served as the key secondary endpoint.¹

Safety and Tolerability

The safety profile observed in Study 304 was consistent with previous lumateperone clinical data and postmarketing experience. No new safety signals were identified. The most common treatment-related adverse event was headache, occurring in at least 5% of patients and at a rate at least twice that of placebo. Notably, there were no clinically relevant increases in prolactin or cardiometabolic parameters at the end of the double-blind treatment period.¹

Supplementary data from a 12-month open-label extension study showed a mean weight change of −2.05 kg (−4.52 lbs) over 1 year, with sustained improvements or stability in metabolic parameters. These findings are notable given that metabolic side effects and extrapyramidal symptoms remain key drivers of antipsychotic discontinuation.²

Clinical Context and Unmet Need

Schizophrenia affects approximately 2.8 million adults in the United States, and roughly 40% of individuals do not receive adequate treatment.³ Relapse remains a central challenge: data suggest that adults with schizophrenia experience an average of 9 relapse episodes within 6 years, each potentially eroding functional gains and increasing hospitalization risk.¹ The societal cost of schizophrenia in the United States was estimated at $366.8 billion in 2024.¹

While several atypical antipsychotics have demonstrated relapse prevention in randomized withdrawal designs, the metabolic and neurologic side-effect profiles of existing agents remain barriers to long-term adherence. Lumateperone's mechanism—characterized by high serotonin 5-HT2A receptor occupancy and moderate dopamine D2 receptor occupancy—may underlie the relatively favorable tolerability profile observed across its clinical program, though its exact mechanism of action remains unknown.¹

Johnson & Johnson has stated that lumateperone is also being evaluated in clinical studies for additional neuropsychiatric and neurological conditions beyond its current approved indications.¹

References

1. Johnson & Johnson. FDA approves CAPLYTA (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia. Press release. May 9, 2026. Accessed May 2026. https://www.prnewswire.com/news-releases/fda-approves-caplyta-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia-302753851.html
2. Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lumateperone (ITI-007) in schizophrenia: a 1-year open-label extension study. Schizophr Res. 2020;228:160-168. doi:10.1093/schbul/sbaa030.517
3. Treatment Advocacy Center. Schizophrenia fact sheet. Updated March 10, 2025. Accessed May 2026. https://www.tac.org/reports_publications/schizophrenia-fact-sheet/
4. Velligan DI, Rao S. The epidemiology and global burden of schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5